Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

0EE0

Uniqure Nv (0EE0)

Uniqure Nv
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:LSE:0EE0
FechaHoraFuenteTítuloSímboloCompañía
27/02/202506:05UK RegulatoryuniQure Announces 2024 Financial Results and Highlights Recent Company ProgressLSE:0EE0Uniqure Nv
03/02/202506:05UK RegulatoryuniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry DiseaseLSE:0EE0Uniqure Nv
30/01/202506:37UK RegulatoryuniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALSLSE:0EE0Uniqure Nv
08/01/202506:05UK RegulatoryuniQure Announces Pricing of its Public OfferingLSE:0EE0Uniqure Nv
07/01/202515:49UK RegulatoryuniQure Announces Proposed Public OfferingLSE:0EE0Uniqure Nv
10/12/202406:05UK RegulatoryuniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s DiseaseLSE:0EE0Uniqure Nv
21/11/202406:05UK RegulatoryuniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe EpilepsyLSE:0EE0Uniqure Nv
05/11/202406:05UK RegulatoryuniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company ProgressLSE:0EE0Uniqure Nv
15/10/202406:05UK RegulatoryuniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALSLSE:0EE0Uniqure Nv
23/09/202406:05UK RegulatoryuniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry DiseaseLSE:0EE0Uniqure Nv
15/08/202406:05UK RegulatoryuniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry DiseaseLSE:0EE0Uniqure Nv
01/08/202406:05UK RegulatoryuniQure Announces Second Quarter 2024 Financial Results and Provides Company UpdateLSE:0EE0Uniqure Nv
23/07/202406:05UK RegulatoryuniQure Announces Closing of Sale of Manufacturing Facility to GenezenLSE:0EE0Uniqure Nv
09/07/202406:05UK RegulatoryuniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s DiseaseLSE:0EE0Uniqure Nv
01/07/202406:05UK RegulatoryuniQure Announces Sale of Commercial Manufacturing Facility to GenezenLSE:0EE0Uniqure Nv
03/06/202406:05UK RegulatoryuniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s DiseaseLSE:0EE0Uniqure Nv
07/05/202406:05UK RegulatoryuniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressLSE:0EE0Uniqure Nv
28/02/202406:05UK RegulatoryuniQure Announces 2023 Financial Results and Highlights Recent Company ProgressLSE:0EE0Uniqure Nv
 Showing the most relevant articles for your search:LSE:0EE0